The reported risks, the theoretical ones, and who should not use it.
GHK-Cu side effects are usually described as mild, but mild is not the same as studied, and the honest position is that large-scale human safety data does not exist. Most of what is known comes from topical use in small studies, cosmetic formulation experience, and laboratory work. This page separates what has actually been reported from what remains theoretical, and names the groups who should avoid copper peptides entirely. For the peptide background, see our GHK-Cu peptide guide; for how copper peptides sit within a wider plan, see longevity and peptide therapy. GHK-Cu is not FDA-approved.
The clearest contraindication is a copper metabolism disorder. People with Wilson disease, in which copper accumulates in the liver and brain, should not use copper peptide preparations, and the same caution applies to other inherited copper handling disorders and to anyone on copper-restricted management. Beyond that, pregnancy and breastfeeding are standard exclusions because safety has not been established, and people with active eczema, open wounds outside a supervised wound care context, or known copper contact allergy should be assessed before any use. Kidney or liver disease that affects mineral handling is another reason for a clinician to say no. This is exactly why a health assessment precedes any prescription rather than following it. Contact your clinician and stop use if you develop spreading rash, blistering, swelling beyond the application area, or any sign of an allergic reaction such as difficulty breathing, which warrants urgent medical care.
Most pages on this topic list two mild effects and pivot straight to a buy button. The useful version names the contraindications, admits the evidence gaps, and tells you when to stop. If you want that conversation with a licensed clinician rather than a checkout page, start with longevity and peptide therapy, or read what the research actually measured on our GHK-Cu before and after page.
With topical use, local skin reactions are the most commonly reported: redness, stinging, itching, or dryness at the application area. Most reports describe these as mild and transient, though individual responses vary and long-term human data is limited.
Copper accumulation is a theoretical concern rather than a documented outcome of prescribed topical use, but it is a real reason to avoid unsupervised systemic use and to screen for copper metabolism disorders first.
People with Wilson disease or other copper metabolism disorders, people with known copper allergy, and anyone pregnant or breastfeeding. Your clinician also assesses skin conditions, kidney and liver health, and current medications.
Yes. Injectable use adds injection site reactions and systemic exposure, with less human evidence behind it. Our GHK-Cu peptide injection page explains why that route is clinician-directed only.
Concentration and frequency both influence irritation risk, which is one reason a prescriber sets them individually. See our GHK-Cu dosage page for how that decision is made.
No. GHK-Cu is not FDA-approved, and compounded preparations are not FDA-approved. Nothing here is intended to diagnose, treat, cure, or prevent any disease.
GHK-Cu is not FDA-approved. This page is educational and is not medical advice or a complete list of possible adverse effects. Compounded GHK-Cu preparations are prepared by US state-licensed pharmacies and are not FDA-approved. Prescription products require an online consultation with a licensed US clinician where clinically appropriate; approval is not guaranteed. Human safety research on GHK-Cu is limited and much of it is preclinical or small-scale. Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results vary.
Start your free consultation right now
No clinic visit. Licensed US clinicians. Dispatched within 24 hours of your consultation and payment.